Cardiogenesis, a CryoLife company, has received FDA clearance to market the company’s new Sologrip III laser fiberoptic delivery device. The Sologrip III is a single use device used along with the company’s Holmium:YAG laser-based transmyocardial revascularization (TMR) system to treat angina.
Minimally invasive TMR procedure involves reaching the heart through an incision between the ribs and then creating 1 mm wide channels in the myocardium that induce the muscle to generate neovasculature. Typically between 20 and 40 such channels are created during the procedure. The technique increases blood and oxygen supply to the diseased part of the heart, improving performance and reducing angina associated pain.
Product page: Sologrip III…
Press release: CryoLife Receives FDA Premarket Approval (PMA) for New Sologrip Minimally Invasive TMR Laser Fiber-Optic Delivery System
